All In Biotech

Drug Trial Radar · NCT05052801

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 547 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

547

Actual

Start

Mar 7, 2022

Primary completion

Jun 20, 2025

Study completion Apr 26, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Zai Lab (China only)
First posted
Sep 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with FGFR2b ≥10% 2+/3+ tumor cell staining (FGFR2b ≥10% 2+/3+TC)

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • BemarituzumabDrug

    Intravenous (IV) infusion

  • mFOLFOX6Drug

    mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Up to approximately 3.5 years

Locations

300 sites in 37 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology

    Anchorage, Alaska

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • The Oncology Institute Clinical Research

    Cerritos, California

  • University of California Los Angeles

    Los Angeles, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Saint Francis Medical Group

    Indianapolis, Indiana

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Healthier Hematology and Oncology Excelsior Integrated Medical Group

    Brooklyn, New York

  • White Plains Hospital Center for Cancer Care

    White Plains, New York

  • Levine Cancer Institute University

    Charlotte, North Carolina

  • FirstHealth Cancer Center

    Pinehurst, North Carolina

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • Medical Oncology Associates, PS

    Spokane, Washington

  • Instituto Argentino de Diagnostico y Tratamiento IADT

    Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    CABA, Buenos Aires, Argentina

  • Hospital Universitario Fundacion Favaloro

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Sociedad de Beneficencia Hospital Italiano

    Córdoba, Córdoba Province, Argentina

  • Hospital Privado Universitario de Cordoba

    Córdoba, Córdoba Province, Argentina

  • Hospital Provincial del Centenario

    Rosario, Santa Fe Province, Argentina

  • Exelsus Oncologia Clinica

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • St John of God Murdoch Hospital

    Murdoch, Western Australia, Australia

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liege - Sart Tilman

    Liège, Belgium

  • Instituto Nacional de Cancer

    Rio de Janeiro, Brazil

  • Hospital Nove de Julho - dasa

    São Paulo, Brazil

  • Instituto Brasileiro de Controle do Cancer Ibcc

    São Paulo, Brazil

  • Núcleo de Oncologia da Bahia

    Salvador, Estado de Bahia, Brazil

  • Centro de Oncologia Mackenzie

    Curitiba, Paraná, Brazil

  • Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinica de Oncologia Reichow

    Blumenau, Santa Catarina, Brazil

  • Centro de Pesquisa e Ensino em Oncologia de Santa Catarina

    Florianópolis, Santa Catarina, Brazil

  • Instituto de Ensino e Pesquisa Sao Lucas Iep Sao Lucas

    Santo André, São Paulo, Brazil

Showing 40 of 300 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.